Cytek Biosciences, Inc. CTKB
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 49.85% | 35.56% | 57.20% | -704.60% | 1.88% |
| Total Depreciation and Amortization | 4.19% | 6.11% | -7.56% | -0.56% | 2.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -30.28% | 46.98% | -90.13% | 1,999.71% | -40.28% |
| Change in Net Operating Assets | -240.51% | -53.41% | 358.94% | 2.47% | -353.89% |
| Cash from Operations | -425.60% | 149.96% | -254.86% | 80.22% | -3,709.26% |
| Capital Expenditure | 31.99% | -2.21% | -116.58% | -52.36% | 58.34% |
| Sale of Property, Plant, and Equipment | 2,266.67% | -50.00% | -96.92% | 19,400.00% | -95.65% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -103.95% | 137.06% | -2,305.12% | -105.29% | 231.75% |
| Cash from Investing | -125.65% | 125.93% | -1,370.09% | -109.74% | 215.27% |
| Total Debt Issued | 2,485.37% | -99.19% | 257.91% | -32.28% | 50.97% |
| Total Debt Repaid | -46.62% | -85.62% | 70.44% | -1,927.59% | -2.11% |
| Issuance of Common Stock | 7.01% | 4,385.71% | -96.05% | 287.59% | -82.14% |
| Repurchase of Common Stock | -43.48% | 23.01% | -2.14% | -64.79% | 96.92% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 31.08% | -120.45% | 424.71% | -163.16% | 174.60% |
| Foreign Exchange rate Adjustments | -73.93% | -6.19% | -54.25% | 66.90% | 191.86% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | 300.00% |
| Net Change in Cash | -181.35% | 132.48% | -937.82% | -113.63% | 189.82% |